Invention Grant
- Patent Title: 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof
-
Application No.: US15755572Application Date: 2016-07-26
-
Publication No.: US11267802B2Publication Date: 2022-03-08
- Inventor: Xiong Cai , Changgeng Qian , Yunwo Weng , Bin Liu , Yanyan Wang , Mingsheng Lin , Junqi Li , Yuanhui Qing , Huajin You , Shiqing Zhou , Weicai Xue
- Applicant: BEBETTER MED INC.
- Applicant Address: CN Guangdong
- Assignee: BEBETTER MED INC.
- Current Assignee: BEBETTER MED INC.
- Current Assignee Address: CN Guangdong
- Agency: JCIPRNET
- Priority: CN201510552982.X 20150831,CN201610471043.7 20160622
- International Application: PCT/CN2016/091755 WO 20160726
- International Announcement: WO2017/036263 WO 20170309
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D403/04 ; A61P35/00 ; C07D401/14 ; C07D403/14 ; C07D413/14

Abstract:
Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.
Public/Granted literature
- US20200331891A9 2,4-BIS(NITROGEN-CONTAINING GROUP)-SUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD AND USE THEREOF Public/Granted day:2020-10-22
Information query